via University of Virginia School of Medicine
A common antidepressant could offer the first treatment for the leading cause of blindness among people over 50, new research from the University of Virginia School of Medicine suggests.
UVA’s Bradley D. Gelfand and collaborators have found early evidence that the drug fluoxetine – marketed as Prozac – may be effective against atrophic (or “dry”) age-related macular degeneration, a condition that affects nearly 200 million people worldwide. The drug has shown promise in the scientists’ lab tests and animal models, and the researchers bolstered their results by examining two huge insurance databases encompassing more than 100 million Americans. That analysis concluded that patients taking fluoxetine for depression were less likely to develop atrophic macular degeneration.
Based on their findings, the researchers are urging clinical trials to test the drug in patients with AMD. If successful, they believe the drug could be administered either orally or via a long-lasting implant in the eye.
“These findings are an exciting example of the promise of drug repurposing – using existing medicines in new and unexpected ways,” Gelfand, of UVA’s Center for Advanced Vision Science, said. “Ultimately, the best way to test whether fluoxetine benefits macular degeneration is to run a prospective clinical trial.”
Fluoxetine and AMD
The researchers believe fluoxetine works against AMD by binding with a particular agent of the immune system known as an inflammasome. This inflammasome, NLRP3-ASC, triggers the breakdown of the pigmented layer of the eye’s retina.
After conducting extensive bench research, Gelfand and his team tested fluoxetine and eight other depression drugs in lab mice to see what effect, if any, the drugs would have in a model of AMD. Fluoxetine slowed the progression of the disease, but the others did not, the scientists found.
Encouraged by their findings, the researchers looked at fluoxetine use among patients over age 50 in two enormous insurance databases. People taking the drug had a “significantly” slower rate of developing dry AMD, the researchers report in a new scientific paper outlining their findings.
They note that their approach, combining bench research with big-data analysis, could potentially facilitate the repurposing of existing drugs for many conditions, speeding new treatments to patients.
“Traditional approaches to drug development can be expensive and time-consuming: On average, a new FDA-approved drug takes 10 to 12 years and costs $2.8 billion (present-day dollars) to develop,” the researchers wrote. “Our identification of the unrecognized therapeutic activity of an existing FDA-approved drug using big data mining, coupled with demonstrating its efficacy in a disease-relevant model, could greatly accelerate and reduce the cost of drug development.”
Gelfand was involved earlier this year in using a similar approach to determine that HIV drugs known as nucleoside reverse transcriptase inhibitors, or NRTIs, may be useful against dry macular degeneration as well.
“While we have had a great deal of success with the approach of using real-world patient data, we may have only begun to scratch the surface of finding new uses for old drugs,” said Gelfand, of UVA’s departments of Ophthalmology and Biomedical Engineering. “It is tempting to think about all the untapped therapeutic potential of medicines sitting on pharmacy shelves.”
More from: University of Virginia School of Medicine
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- Hepatitis C drug may reduce antibiotic resistance, researchers say
A hepatitis C drug, telaprevir, can block the function of essential proteins in bacteria, which may allow to it be repurposed to limit antibiotic resistance, a study released Tuesday showed.
- ALS Drug Could Be Repurposed To Treat Rare Childhood Genetic Disorder
Riluzole, a drug approved to treat amyotrophic lateral sclerosis, could slow the loss of a particular brain cell that occurs in Niemann-Pick disease type C, a rare genetic disorder affecting children ...
- Repurposed ALS Drug Against Rare Genetic Disorder
Repurposed ALS (amyotrophic lateral sclerosis) drug may help slow down a rare genetic disorder in children and adolescents.
- UPMC: Novel Computational Pipeline Could Help Repurpose Cancer Drugs for Rare Diseases
By combining computational and experimental approaches, University of Pittsburgh School of Medicine and Prairie View A&M University researchers identified cancer drugs that show promise for treating ...
- Potential Alzheimer’s Treatments Discovered in Analysis of Existing Cancer Drugs
NIH research highlights importance of data-driven approach to identify novel drug targets. Existing and emerging cancer drugs could be repurposed as therapies to be tested in clinical trials for ...
Go deeper with Google Headlines on:
Go deeper with Bing News on:
Fluoxetine and AMD
- Orange Book
For Prozac, you would search the Orange Book for “fluoxetine hydrochloride.” To be able to market and sell a generic drug, the generic drugmaker must file an Abbreviated New Drug Application ...
- Best Medicare Part D Providers
If a formulary doesn’t cover your prescription, it may cover a similar or generic medication (think Tylenol vs acetaminophen, or Prozac and fluoxetine). Your doctor may also be able to negotiate ...
- Prozac pegged as potential treatment for macular degeneration
That analysis concluded that patients taking fluoxetine were less likely to develop atrophic macular degeneration (AMD). Based on their findings, the researchers are urging clinical trials to test ...
- Repurposing drugs to treat age-related macular degeneration
Researchers found that the antidepressant fluoxetine blocks the inflammation that leads to dry age-related macular degeneration (AMD), a common cause of vision loss. Health insurance data showed that ...
- How the antidepressant Prozac could treat blindness
New drugs take about a decade and billions of dollars to develop, which makes repurposing existing drugs an attractive option. There is no treatment for age-related macular degeneration, the ...